UCB Wins FDA Approval for Plaque Psoriasis Therapy After Regulatory Setbacks

The FDA on Wednesday approved UCB’s bimekizumab for the treatment of adults with moderate-to-severe plaque psoriasis. The treatment will be sold under the brand name Bimzelx.

Bimzelx is a humanized IgG1 monoclonal antibody that works by targeting IL-17A and IL-17F, both central players in the inflammatory cascade. Bimzelx is the first FDA-approved plaque psoriasis medication that inhibits both cytokines, according to UCB’s announcement.